Health Care Fraud Liability for Pharmaceutical Manufacturers

DSpace/Manakin Repository

Health Care Fraud Liability for Pharmaceutical Manufacturers

Citable link to this page


Title: Health Care Fraud Liability for Pharmaceutical Manufacturers
Author: Williams, Jennifer Adrienne
Citation: Jennifer Williams, Health Care Fraud Liability for Pharmaceutical Manufacturers (April 2011).
Full Text & Related Files:
Abstract: Fraud is an increasingly expensive cost to the health care industry, and the regulatory and prosecutorial focus during the fast few decades have focused on health care fraud by pharmaceutical manufacturers. This paper provides an overview of the current statutory and judicial environment. First, it examines some of the industry practices for which pharmaceutical companies may be held liable for fraud (as well as some of the reasons these practices are problematic). It then gives an overview of the dual regime of the Medicare and Medicaid Anti-Kickback Statute and the False Claims Act (“FCA”), as well as some of the other guidance documents available to pharmaceutical manufacturers. It also explores the relevant case history that has shaped liability—for health care providers and suppliers in general and for drug companies in particular—under the Anti-Kickback Statute and the FCA. The 2009 settlement between Pfizer and the government provides a useful example of the present state of affairs for pharmaceutical companies. Finally, the paper concludes with a brief overview of the Medicare Part D prescription drug benefit (and the newly implemented coverage gap discount program), which may result in increasing liability for pharmaceutical manufacturers in the future.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search